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32 The Journal of Thoracic and Cardiobjective: In 1984, the first successful infant heart transplant was performed at
exas Children’s Hospital. This study analyzes the 21-year experience with pedi-
tric heart transplantation at Texas Children’s Hospital to assess whether and how
urvival has changed over time.
ethods: Between November 1, 1984, and October 3, 2005, 164 consecutive
rthotopic heart transplants were performed on 154 patients. Characteristics: mean
ge 7.1  6.0 years, mean body surface area 0.8  0.5 m2. Diagnosis at transplant:
ardiomyopathy 53.0% (n  87), congenital heart defect 39.0% (n  64), retrans-
lant 7.9% (n 13). Multivariate risk factor analysis of 32 variables was completed
y Cox proportional hazards regression models.
esults: Mean follow-up was 5.9  4.8 years. Overall Kaplan–Meier survival was
2% at 1 year, 65% at 5 years, and 54% at 10 years. After 1995, Kaplan–Meier
urvival (91% at 1 year and 71% at 5 years) was significantly improved over
re-1995 survival (71% at 1 year, 57% at 5 years, and 48% at 10 years; P .026).
ospital survival improved in the post-1995 era (96%) compared with the pre-1995
ra (77%; P  .001). Life-table analysis by yearly increments demonstrates only an
mproved survival (pre-1995, 71%¡post-1995, 91%) in the first posttransplant year
P  .001); every subsequent year the mortality rates are the same (P  .92). Risk
actors for overall mortality are prolonged postoperative intubation (5 days) and
onger cardiopulmonary bypass time.
onclusions: Primarily attributable to an increase in early survival, overall pediatric
eart transplant survival is improved. However, after the first posttransplant year,
he rate of mortality has not changed in 21 years. This highlights the need for new
herapies to treat children both with or in need of a heart transplant.
n December 6, 1967, Dr Adrian Kantrowitz and his associates 1 in Brooklyn,
New York, performed the first pediatric heart transplant on a 17-day-old
infant with Ebstein anomaly. This occurred just 3 days after Dr Christian
arnard’s2 first human-to-human transplant on December 3, 1967, in South Africa. 3
n 1984, nearly 20 years later, the first successful infant heart transplant was
erformed by Dr Denton Cooley and his colleagues4 on an 8-month-old girl at Texas
hildren’s Hospital (TCH).
Pediatric heart transplantation has become an accepted management strategy for
ediatric patients with end-stage heart failure resulting from cardiomyopathy or
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Dnoperable congenital heart disease (CHD). Since 1982,
ore than 6000 pediatric heart transplants have been per-
ormed, with consistent improvement in survival.5 Increas-
ng early survival, most likely a manifestation of the ad-
ancements in perioperative management, has been the
riving force improving outcomes.5,6 Although not statisti-
ally proven, the rate of late attrition of pediatric patients
ndergoing heart transplantation has seemingly not changed
ince the advent of cyclosporine in the early 1980s.4,5,7,8 No
herapies in the past 20 years have significantly changed the
ate of chronic rejection; thus, the uncertainty of long-term
urvival remains. The objective of this study is to review the
1-year experience with pediatric heart transplantation at a
ingle institution, assessing how survival has changed over
ime and the variables that affect survival.
atients and Methods
retrospective analysis of all pediatric heart transplants per-
ormed at TCH between November 11, 1984, and October 3, 2005,
as completed with the permission of the Internal Review Board
f Baylor College of Medicine. There were 165 consecutive heart
ransplants performed on 155 patients. One patient received a
eterotopic heart transplant and his data are excluded from all
nalyses.
Mean age at transplant was 7.1 6.0 years (median 5.2 years [20
ays-21 years]), with a mean body surface area of 0.8 0.5 m2. Age
istribution at time of transplantation was as follows: 17.7 % (n 29)
nfants (age  1 year old), 48.8% (n  80) children (1 year old 
ge 11 years old), and 33.5% (n 55) adolescents (11 years old
age  20.3 years old). Four patients were older than 18 years, all
f whom had CHD. Diagnoses at transplant were cardiomyopathy in
3.0% (n  87 [dilated 70% (61), restrictive 16% (14), hypertrophic
% (7), other 6% (5)]), congenital heart defect in 39.0% (n  64 [ie,
ypoplastic left heart syndrome 16, D-transposition of the great ar-
eries 11, failing Fontan circulation 7]), and cardiac graft failure
.9% (n  13). Ethnic diversity in this series consisted of 46.3%
hite (n  76), 29.9% Hispanic (n  49), 18.9% African Amer-
can (n  31), and 4.9% other (n  8). Patients had a mean of
.9  1.1 (0-5) prior cardiac operations. Pulmonary vascular resis-
ance index (PVRI) was calculated on 67% (104) of the transplant
andidates with an average PVRI of 3.1  2.1 Wood units · m2
0.2-10.5 Wood units · m2). Preoperative patient characteristics are
isted in Table 1.
Concomitant procedures were performed in 38% of transplants
n 63) and consisted of donor patent foramen ovale closure in 9.1%
Abbreviations and Acronyms
CHD  congenital heart disease
ISHLT International Society for Heart and Lung
Transplantation
MMF mycophenolate mofetil
PVRI  pulmonary vascular resistance index
TCH  Texas Children’s Hospitaln  15), mechanical circulatory support removal in 9.1% (n  t
The Journal of Thoracic5), pacemaker removal in 8.5% (n 14), shunt takedown in 8.5%
n  14), aortic arch reconstruction in 8.5% (n  14), complex
ulmonary artery reconstruction in 5.5% (n  9), mechanical
irculatory support placement in 1.8 % (n  3), kidney transplant
n 1.2% (n  2), and other in 6.7% (n  11). Mean cardiopulmo-
ary bypass time was 144  68 minutes (35-490 minutes).
The donor graft is presently perfused with Celsior solution, and
or patients less than 1 year old, a noncommercial buffered hy-
erkalemic extracellular solution (Melbourne solution) is used.
iatrial anastomoses were performed exclusively until 1995 (n 
8). After 1995, transplants were routinely performed by a stan-
ard bicaval anastomotic technique with caval and pulmonary
rtery anastomoses completed with the heart beating. Inhaled nitric
xide was first used for transplant patients at TCH in June of 1994.
Presensitized patients (panel reactive antibodies by flow cytom-
try to class I and class II HLA antigens greater than 10%) were
1) listed with unacceptable antigens based on specific HLA anti-
ody titrations, (2) preoperatively treated with intravenous immu-
oglobulin and rituximab, and/or (3) transplanted with an ex-
hange transfusion on cardiopulmonary bypass and, if there was a
etrospective positive cross-match, treated with plasmapheresis,
ntravenous immunoglobulin, and rituximab. The immunosuppres-
ive protocol has not included induction therapy. Patients routinely
eceive mycophenolate mofetil (MMF) (20 mg/kg) (previously
zathrioprine 1mg/kg) preoperatively and methylprednisone (10
g/kg) intraoperatively. Postoperatively, the patients receive and
re discharged on triple immunosuppressive therapy: a calcineurin
nhibitor, an antimetabolite, and steroids. Tacrolimus was first used
n October of 1998 but was not regularly prescribed until 2002;
ince then, it has been used in 47% (17/36) of patients. Patients are
ollowed up frequently in clinic and with endocardial biopsies for
ABLE 1. Patient variables analyzed for risk factors





Inotropic support 74 (48%)
Renal insufficiency* 7 (5%)
Mechanical circulatory support 12 (8%)
PVRI  5 Woods units  m2 all 22 (14%), fixed 13 (8%)
Prior sternotomy 76 (49%)
ostoperative morbidities
Prolonged postop intubation 27 (18%)
Renal insufficiency* 14 (9%)
Mechanical circulatory support 7 (5%)
Arrhythmia 47 (31%)
Receiving blood products 82 (53%)
Inhaled nitric oxide therapy 26 (17%)
Infection 47 (31%)
Mediastinal infection† 5 (3%)
Bleeding† 15 (10%)
ts., Patients; PVRI, Pulmonary vascular resistance index. *Requiring
ialysis. †Requiring reoperation.he first year, after which a clinic visit or biopsy is every 6 months.
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Datients were considered lost to follow-up if contact by TCH had
ot been made within 18 months of the study’s completion.
Rejection was considered to be a biopsy score of the Interna-
ional Society for Heart and Lung Transplantation (ISHLT) grade
A or higher or the clinical suspicion of rejection regardless of
iopsy score. Acute cellular rejection on the basis of histologic
xamination only without evidence of hemodynamic changes was
reated with pulsed steroids. However, if there was hemodynamic
ompromise, then first-line therapy was either antithymocyte glob-
lin or OKT3 (monoclonal antibody to CD3 positive T cells). The
CH immunosuppressive regimen was recorded and the incidence
f rejection was analyzed for the cohort of patients receiving a
rimary cardiac transplant after 1998 (n  70), when MMF be-
ame the primary antimetabolite and tacrolimus use began (Table 2).
tatistical Methods
escriptive statistics for nominal and numerical data included
atios, medians with ranges, and means with standard deviations.
he 2 test was used to compare hospital and 1-year survivals
etween the early and late eras. All risk factor and Kaplan–Meier
nalyses were based on the patient’s first transplant at TCH (n 
54). Survival analyses were performed with the Kaplan–Meier
ethod and then compared with the log-rank test. All survivals are
aplan–Meier unless the ratio of survivors to patients in the cohort
f interest is specified. Early era (November 1984 to July 1995;
 66) and late era (July 1995 to October 2005; n  88) survival
as also analyzed in yearly increments with the Cutler–Ederer
ethod (life-table analysis) to determine the probability of sur-
ival within each 1-year time period of follow-up, independent of
urvival before or after that 1-year interval. Comparison of early
nd late era life tables was performed with the Wilcoxon–Gehan
tatistic.
Thirty-two covariates were organized according to clinical cat-
gories as follows: (1) patient variables, (2) donor variables, and
3) intraoperative and postoperative variables (Appendix 1). Donor
raft data were supplied by the United Network for Organ Sharing
esearch division and were only available after 1987, capturing
1% to 90% of the TCH cohort depending on the variable. Mul-
ivariate risk factor analyses were completed for discrete and
ontinuous variables by the Cox proportional hazards model. Sig-
ificant risk factors found from these analyses, excluding contin-
ous variables, were further analyzed by odds ratios with 95%
onfidence intervals to determine whether they were independent
isk factors. Overall mortality, 1-year mortality, 5-year mortality,
nd 5-year mortality conditional on 1-year survival were tested for
isk factors. For the 104 patients who had PVRI data, a separate
ABLE 2. Immunosuppression regimen for all primary tran
D/C (n  70) D/C % 1 y (n  56)
yclosporine A 53 76% 34
acrolimus 17 24% 22
rednisone 70 100% 56
MF 54 77% 28
zathioprine 0 0% 0
apamycin 3 4% 5
/C, Discharge; F/U, most recent clinic visit; MMF, mycophenolate mofetiox proportional hazards model including all patient variables i
34 The Journal of Thoracic and Cardiovascular Surgery ● Marcas used to determine whether PVRI as a continuous variable
as a risk factor for overall and conditional 5-year mortality.
ll analyses were conducted with SPSS 13.0 (SPSS, Inc, Chi-
ago, Ill).
esults
ostoperative morbidity is listed in Table 1. The median
ength of intubation was 1 day (0-164 days). The median
ntensive care unit and hospital lengths of stay were 7 days
0-164 days) and 17 days (0-169 days), respectively. Hos-
ital and 1-year survivals for the post-1995 era (96% [84/
8] and 91% [80/88]) were significantly higher than for the
re-1995 era (77% [51/66] and 71% [47/66]) (P  .001,
 .003).
The median wait time (n  146, 89% capture) for a
ecipient on the United Network for Organ Sharing list was
1 days (0-498 days). The median donor age (n 147, 90%
apture) was 4 years (0-28 years) and the median weight
atio (n  134, 82% capture) was 1.2 (0.7-3). In regard to
onor-recipient gender pairing (n  137, 89% capture), the
umber of male donor to female recipients was 35 (54% of
ll female recipients) and of female donors to male recipi-
nts was 37 (37% of all male recipients). Comparing each
f the gender-mismatched recipient cohorts with their
espective gender-matched recipient cohorts revealed
ender-mismatched male recipients to have a lower sur-
ival, with 49% survival at 10 years versus 78% for
ender-matched male recipients (P  .053). Median donor
schemic time reported by TCH records was 232 minutes
68-452 minutes).
From January of 1999 to October of 2005, 61% (43/70)
f patients had rejection during the first year of transplant,
ith 40% of this group (17/43) having only one episode of
ejection. The Kaplan–Meier survival curves of those pa-
ients with and those without rejection in the first year were
ot significantly different (P  .35).
The overall length of follow-up was 5.9  4.8 years
0.4-19.5 years). There are 95 (62%) living patients (79%
re followed up at TCH and 21% by adult specialists), and
1% are in New York Heart Association class I. One patient
0.6%) was lost to follow-up. Overall Kaplan–Meier sur-
ival (1 year, 82.3%; 5 years, 65.3%; and 10 years, 54.4%)
nts after 1998
1 y % 5 y (n  13) 5 y % F/U (n  56) F/U %
61% 9 69% 32 57%
39% 4 31% 24 43%
100% 13 100% 55 98%
50% 4 31% 24 43%
0% 0 0% 0 0%
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Dll, with 34% (n  20) from transplant coronary artery
isease (diagnosed premortem and postmortem), 25% (n 
5) from postoperative multisystem organ failure, 14% (n
) from rejection, and all other causes having a frequency of
% or less. Survival is statistically greater in the late era (30
ays, 100%; 1 year, 91%; and 5 years, 71%) compared with
he early era (30 days, 89%; 1 year, 71%; and 5 years, 57%)
P  .026) (Figure 1, A). Life-table analysis of the early and
ate eras demonstrates that the probability of survival in the
rst year was significantly different (early 71% vs late 91%;
 .001) between the eras, but after the first year, the
robability of survival for each 1-year interval of follow-up
s statistically the same (P  .92) between the eras (Figure
, B). Pre-1995 and post-1995 survivals censored for mor-
ality in the first year are not statistically different (Figure 2).
urvival analysis for patients with the preoperative diag-
oses of cardiomyopathy versus CHD demonstrated no
ifference (P  .68). Early (1-year) survival for patients
ith CHD was significantly higher in the late era (92%,
6/39) than in the early era (68%, 17/25) (P  .011).
omparison of the survival curves for the different age
roups demonstrated that infants’ survival was worse than
igure 1. A, Kaplan–Meier survival analysis overall and by era of
ransplant. B, Cutler–Ederer life-table survival analysis by era.hat of children (P  .03) and adolescents (P  .013). *
The Journal of Thoracicnalysis of the age cohorts by era demonstrates that the
nfants in the late era (30 days, 100%; 1 year, 88%; and 5
ears, 60%) have a significantly higher survival than in the
arlier era (30 days, 58%; 1 year, 33%; and 5 years, 33%)
P  .012). In the late era, infant survival was not different
rom that of the 1- to 10-year-old (P  .538) and the 11- to
0-year-old (P  .717) cohorts. Comparison of conditional
-year survival between the age groups demonstrates that
he 11- to 20-year-old cohort did have a significantly lower
urvival (67%) than those younger than 11 years old (infants
0% and children 86%) (P .025). Independent risk factors
or overall, 1-year, 5-year, and conditional 5-year mortality
re listed in Table 3. PVRI, analyzed as a continuous
ariable, was not a risk factor at any level for overall or
-year conditional mortality.
igure 2. Kaplan–Meier analysis of overall survival censored for
-year mortality: early versus late era.
ABLE 3. Risk factors for mortality
ariable N OR 95% CI
isk factors for overall mortality
Intubated  5 days postop 27 2.358 1.015-5.476
CPB time* (P  .031) 143
isk factors for 1-year mortality
Inpatient 87 2.559 1.011-6.476
Age  1 y 28 3.562 1.410-8.998
Early era 66 4.043 1.080-9.955
Intubated  5 days postop 27 7.495 2.936-19.132
Postop arrhythmia 47 3.711 1.573-8.755
Aortic arch reconstruction 14 4.250 1.338-13.499
isk factors for 5-year mortality
Intubated  5 days postop 27 3.871 1.638-9.151
isk factors for 5-year mortality
conditional on 1-year survival
White (protective) 58 3.750 1.169 to 12.030
Donor age* (P  .013) 116
R, Odds ratio; CI, confidence interval; CPB, cardiopulmonary bypass.
Analyzed as continuous variables in Cox regression hazard model only.







































































































ore than two decades of experience at a single institution
ith pediatric heart transplantation has allowed the unique
pportunity to analyze how survival has changed over time.
he results of the current series substantiate the observa-
ions of the 2005 ISHLT registry in that survival in the late
ra of pediatric heart transplantation is significantly greater
han in the earlier era.5 This difference is clearly driven by
n improvement in early survival as highlighted in the
urrent series by the significant increase in the post-1995
ospital (96% vs 77%) and 1-year (91% vs 71%) survivals
hen compared with the pre-1995 era. This improvement in
arly survival is likely due to the progress in critical care
nd operative management of transplant patients and, in
articular, patients with CHD and infants. In the present
eries, the early (1-year) survival of infants between the eras
post-1995 88% vs pre-1995 33%) clearly improved, to the
xtent that in the modern era, infant survival was the same
s for children and adolescents. Previous series have found
hat patients with cardiomyopathy fared better than those
ith CHD.5 However, the current series, like other large
ingle-center series, have found their survivals to be simi-
ar.9,10 This is probably secondary to the significant ad-
ancements in the perioperative care of patients with CHD
ndergoing cardiac surgery in general. These improvements
re evidenced in this series by the significant increase in
arly survival for patients with CHD between the early
68%) and the late (92%) eras. Also, CHD patients present-
ng for transplant in the modern era are better palliated,
erhaps making them superior transplant candidates.
As reported by other authors and supported by the TCH
esults, when comparing the early and modern experiences
ith pediatric heart transplantation, the rate of mortality (ie,
he slope of the Kaplan–Meier survival curve) after the first
ear is the same.5 In an attempt to quantify this observation,
e used the Culter-Ederer method to analyze the pre-1995
nd post-1995 survivals in yearly increments to determine
he probability of survival over each 1-year period of follow-
p. This analysis revealed that during the first year after trans-
lant, the pre-1995 cohort had a 71% chance of survival,
ignificantly lower than the 90% chance for the post-1995
ra. However, the probability of survival in every subse-
uent 1-year interval was not statistically different between
he eras and averaged 95% for the early era and 96% for the
ost-1995 era. This was further verified by creating survival
urves for the pre-1995 and post-1995 eras that censored
arly mortality so that a direct comparison of midterm and
ate survival was possible without early mortality contami-
ation. These curves are not significantly different and, in
act, are virtually identical (Figure 2). Therefore, after the
rst post-transplant year of follow-up, the mortality rate for
ediatric heart transplantation has not changed in more than t
36 The Journal of Thoracic and Cardiovascular Surgery ● Marc0 years, despite shifting trends in immunosuppression (ie,
ncreased use of MMF and tacrolimus).
In addition to survival analyses between eras, the lon-
evity of the TCH series allowed survival analysis of mul-
iple factors that could affect survival. Male recipients who
eceived female donor hearts had a decreased survival com-
ared with male recipients who were donor gender matched.
atient status permitting, gender-matched donor selection
or male recipients could result in improved survival.11,12
Prolonged intubation was the most consistent and dom-
nant risk factor, in that it increased the risk of death overall
s well as at 1 and 5 years, more than any other risk factor.
he transplant team’s aggressive policy toward extubation
as resulted in a median length of cumulative intubation of
day. Therefore, the inability to extubate a patient within 5
ays after transplantation clearly indicated a poor clinical
ourse, as evidenced by the 56% mortality (15/27) seen in
his cohort. Prolonged intubation is more likely a reliable
redictor for death than a cause.
Risk factors for 5-year mortality conditional on 1-year
urvival allow the effect of early mortality to be eliminated
o that risk factors reflect the true risks for late mortality.
eing white increased the probability of survival at 5 years
nce early mortality was censored. Differences in pediatric
ost–heart transplant survival among ethnic groups have
een documented before. Series have found Hispanic and
frican American patients (91% of TCH’s non-white co-
ort) to be at increased risk for recurrent rejection and thus
eath.10,13 Increasing donor age was an independent risk
actor for conditional 5-year survival. This has been dem-
nstrated in another pediatric series that had a proportion of
lder (40 years) donors, but in the current series, only 4 of
he donors were more than 20 years old with the oldest
eing 28 years old.14 Another possible explanation is that
he adolescent cohort, who has a significantly lower 5-year
onditional survival, contains the patients most likely to
eceive older donor hearts. Therefore, perhaps increasing
onor age is serving as a surrogate to identify the adolescent
roup, which has been recognized by multiple centers to
ave an increased rate of late attrition, primarily related to
ompliance issues.5,15
Since the 1980s, pediatric heart transplantation has become
safe and effective management strategy for pediatric patients
ith end-stage heart failure. Improving survival in pediatric
ardiac transplantation is predominately related to increased
arly survival. For patients surviving the first posttransplant
ear, the subsequent mortality rate has not changed in more
han 21 years. This highlights the ongoing need for novel
herapies to treat children with or in need of a heart transplant.
We thank Sarah Clunie, RN, for her tireless dedication to and
are of these patients. We also thank Brandi Braud and Justin
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iscussion
r Vaughn A. Starnes (Los Angeles, Calif). Dr Morales and
ssociates are to be congratulated on an excellent paper retrospec-
ively reviewing 21 years of experience at the TCH. During that
ime, they performed 165 transplants on 155 recipients. As noted
n the paper, children with cardiomyopathy made up more than
0% of the patients, another approximately 40% were children
ith CHD, and 7.9% were children with graft failure.
As noted by the author, this series compares favorably with the
nternational Registry of Heart and Lung Transplant survival sta-
istics and the causes for transplant.
As we see in this report, as also true of the registry, our
mprovement in survival over time has been primarily related to
ur early graft survival, particularly in the first year after the
ransplant event. As noted by these authors, an increase of 20%
ver this decade between 1995 and after 1995, it increased from
The Journal of ThoracicPPENDIX 1. Thirty-two variables analyzed to determine
isk factors for mortality and definitions






Early era November 1, 1984-June 30,
1995
ge
Age  1 year old





Hypoplastic left heart syndrome
Failing Fontan circulation
ody surface area (m2)* ([Height (cm)  Weight
(kg)]/3600)1/2
npatient Hospital admission  24
hours before transplant


















enal insufficiency‡ Requiring dialysis
rolonged intubation‡  5 cumulative days of
intubation
echanical circulatory support‡
rrhythmia Recurrent and/or requiring
treatment
eceiving blood products Any blood product during
intensive care unit stay
nfection Positive culture and
antibiotic treatment
nhaled nitric oxide therapy‡
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D1% to 91% during that period of time; that survival statistic
aralleled the course over the next 5 to 10 years.
The authors bring up some interesting findings that are also true
n the registry, that ethnicity does affect survival, with the pediatric
hite population faring better than the African American or His-
anic transplant recipients.
The other interesting factor was that the mismatch between
enders was very compelling. The mismatch of a male recipient
eceiving a female donor heart had a significant importance over
ime and, in fact, at 10 years the survival difference was 49%
ersus 70%. I thought that was a very compelling argument about
rying to match gender.
I have three questions.
The ISHLT reported a significant negative impact with an odds
atio of 2.1 on the influence of CHD as a pretransplant diagnosis
n the outcome of the recipient. You found no statistical difference
etween the cardiomyopathy group and the CHD group. Could you
xplain that?
Dr Morales. I think if we look into the two different eras, in the
re-1995 era it was a risk factor. In the post-1995 era, in which we
ow have a dedicated congenital heart surgery center, including
urgeons, anesthesiologists, and intensivists, CHD is no longer a
isk factor because of the large improvement in early survival. I
elieve that this is why, overall, it did not come out as a risk factor
n our analysis.
Dr Starnes. My second question concerns the negative impact
f prolonged intubation. With your odds ratios on 1- and 5-year
urvivals (7.4 and 3.8, respectively) as a negative impact of this
actor, I would view this more as a surrogate for a very sick
retransplant patient with other comorbidities. Are you suggesting
hat intubation is an independent risk factor outside of the comor-
idities that might go along with that?
Dr Morales. I agree with you that it probably has something to
o with their pretransplant status; however, the statistical analysis
ould say that prolonged intubation is itself an independent risk
actor for mortality.
Dr Starnes. Again, regrettably, the long-term outcome has
emained the same over the past 20 years, and the survival beyond
years is still affected by coronary artery disease, with death due
o coronary disease representing 30% to 35% in most series and
4% in your series. Given this, has your group taken on any novel
mmunosuppressive approaches? I noted in your manuscript that
ome 5% of your patients were receiving rapamycin.
Dr Morales. When a patient has transplant artery coronary
isease, one thing that we have changed in the past 5 to 8 years is
rescribing rapamycin. Almost all of our applications of rapamy-
in are for transplant coronary disease. We have also started
rescribing pravastatin (Pravachol) as possible prophylaxis against
ransplant coronary disease once the patients reach adolescence.
Dr Roland Hetzer (Berlin, Germany). I want to congratulate
he Houston group for this enormous experience. Our own activ-
ties among more than 1500 heart transplants include 140 infants
nd children under the age of 18 years during the past 20 years.
ur 10-year survival in this transplanted group was 70%. We have
ttributed this to very close, meticulous monitoring of rejection by
lectrophysiologic telemetric methods.
I would like you to comment on several issues: the mode of
ejection monitoring in children and infants, the impact of chronic i
38 The Journal of Thoracic and Cardiovascular Surgery ● Marcenal failure at long term, the obvious lack of compliance in
dolescents, and the diagnostics of transplant vasculopathy, which
e have found to be an important factor for survival beyond 10
ears after transplantation.
Dr Morales. In terms of how we monitor these children for
hronic rejection or acute rejection, we do myocardial biopsies
very 2 weeks during the first 3 months, then every 3 months for
he first year, then every 6 months for the next 4 years, and yearly
hereafter. Our cardiology colleagues also do a great job at clini-
ally following these children quite frequently and often will
iagnose a change in their clinical status. At 3 months, we do
oronary angiography as a baseline and then follow that up with
early angiograms to diagnose coronary disease.
Renal failure played a significant cause in only 1 of the 59
eaths in this series, so it actually has not played a major role in
ur series in regard to mortality. However, it certainly is a widely
nown morbidity in these patients, whose renal function we follow
losely. Two of our patients have required renal transplant.
Adolescent noncompliance has always been a problem, and as
ou have seen in our slide on conditional 5-year survival, it
efinitely has a negative impact on late survival. As do most
rograms, we pride ourselves in developing close and strong
elationships with our patients, so through our counseling we try to
mprove compliance.
Dr Cooley. In that initial operation that we did on an 8-month-
ld infant, our concern was, then, about the possibility of the
nfluence of immunosuppressive drugs on growth and develop-
ent. It was very gratifying to see how that little girl grew and
ecame intelligent; she was a good student in school and so forth.
t was a real tragedy when she did pass away from coronary
cclusive changes.
I missed it in the donors involved. The situation with the donor
n our first transplant was rather complex. The donor was another
nfant from Dallas, Texas. The mother and father, in a fit of anger,
ad thrown the child out of a second-story window and the child
ustained severe brain injury. To get the permission for the dona-
ion, we had to go to the jail in Dallas where the mother and father
ere incarcerated. We brought the baby down to Houston and had
he little recipient available. The recipient was an adopted child. So
he situation became rather complicated.
I missed it in your policy now at TCH about ABO mismatch in
andidates for transplantation. I hear reports of other institutions
hat are using ABO mismatch. What is the policy at the Children’s
ospital in Houston?
Dr Morales. Thank you, Dr Cooley, for your comments. It is
uite an honor to have you here at this presentation to give all of
s perspective on this field. I am aware that Toronto has had good
uccess with the ABO mismatch. However, we have not performed
ny ABO mismatch transplants at TCH. It is something that our
ardiologists are interested in and they have been investigating this
ption, but as of this time we have not applied this donor man-
gement strategy.
Dr Lucio Parenzan (Bergamo, Italy). To find a small heart, as
ou know, is difficult. Many times you have to fly many hours.
hat do you think about the new system they have in Germany
here they are perfusing the heart during the transplantation? Do
ou have any data? Do you have any knowledge? Do you think it
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I can say that we did analyze ischemic time, with maximum
schemic time being 7.5 hours, as a continuous variable to see
hether it was a risk factor for mortality. Our analysis demon-
trated that at no time was ischemic time a risk factor for death.
owever, having said that, there obviously is an ischemic time in
hich graft function and mortality would be affected negatively,
ut it is unclear to me that it is at 4 hours, as we have always been
aught.
Dr Adnan Cobanoglu (Cleveland, Ohio). I would like to find
ut more about the retransplants. There were 13 patients. How was
he outcome in the retransplantation group?
Dr Morales. We calculated Kaplan–Meier survival curves of
he 13 retransplants and of all the primary grafts, and we comparedThe Journal of Thoracicohorts. However, I do not know how much can be gathered from
hat analysis, since there were only 13 retransplants. Having said
hat, our belief now is that their survival is about the same, but we
ill have to see whether that is true as our numbers and length of
ollow-up increase.
Dr William A. Baumgartner (Baltimore, Md). You said isch-
mic time is not related to rejection or survival. Increasing evi-
ence suggests that there is a relationship between ischemic time,
r injury at the time of procurement, and the future development of
oronary artery disease. Have you looked at this correlation?
Dr Morales. We did not look at the issue of ischemic time and
hronic rejection in particular. We did show that, at least in our
eries, ischemic time was not related to death or graft failure in
eneral. This issue of ischemic time and chronic rejection is anCH
Dhe two groups. We did not find a statistical difference between the interesting one that we should investigate in our series.and Cardiovascular Surgery ● Volume 133, Number 3 639
